Fernández-Martos C, Pericay C, Losa F, et al. - Researchers performed the Grupo Español Multidisciplinar En Cancer Digestivo (GEMCAD) 1402 phase 2 randomized clinical trial, in order to assess the effect of aflibercept plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) induction chemotherapy prior to standard chemoradiotherapy and total mesorectal excision surgery in patients with high-risk rectal adenocarcinoma. Pathologic complete response of 22.6% vs 13.8% with vs without aflibercept was observed, respectively, with no substantial increase in surgical complications. A rationale for phase 3 trials was gained in the GEMCAD 1402 trial.